Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
76 participants
INTERVENTIONAL
2024-09-30
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Modified Suanzaoren Decoction Versus Eszopiclone for the Treatment of Chronic Insomnia Disorder
NCT06452953
Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder
NCT05525637
Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia Disorder
NCT06279286
"Chou's Tiaoshen" Acupoints for Short-term Insomnia.
NCT06212934
A Study of Ramelteon in Chinese Patients With Chronic Insomnia
NCT06512363
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Chinese medicine can be an alternative to the treatment of insomnia. Suan Zao Ren Tang and Tian Wang Bu Xin Dan are two of the most common Chinese herbal formulae to treat insomnia, for which Suan Zao Ren Tang has the functions to nourish blood and calm the mind, clear heat and alleviate vexation, and Tian Wang Bu Xin Dan has the function to nourish the heart and calm the mind, and nourish Yin and clear heat. In this study, we will modify the formula of Suan ZaoRen Tang with TianWang BuXin Dan, and observe the effectiveness and safety of the study drug.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
mSZT-TBD granules
Modified Suan ZaoRen Tang-TianWang BuXin Dan granules
Modified Suan ZaoRen Tang-TianWang BuXin Dan
Chinese medicine granules for 6 weeks
Placebo granules
Placebo granules
Placebo
Placebo granules for 6 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Modified Suan ZaoRen Tang-TianWang BuXin Dan
Chinese medicine granules for 6 weeks
Placebo
Placebo granules for 6 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eligible for the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, criteria for insomnia disorder. The criteria include having difficulties in falling asleep, difficulties in staying asleep, or early morning awakening with clinically significant consequences for daily life for at least 3 nights per week for at least 6 months;
* Insomnia Severity Index (ISI) total score of at least 8 indicating insomnia at the clinical level;
* Diagnosed to be Yin deficiency-induced internal heat pattern according to traditional Chinese Medicine (TCM) theory;
* Able to complete questionnaires and take medications as scheduled; and
* Voluntary written consent.
Exclusion Criteria
* Known mental disorders (eg, depression or anxiety) or HADS score 11 or above in any either item;
* Known sleeping related diseases (eg. sleep apnea, nocturnal myoclonus, restless legs, severe nocturnal enuresis or narcolepsy) that may affect the sleeping quality;
* Known pharmacologically induced insomnia;
* With symptoms that significantly disturb sleep such as pain, fever, diarrhea, frequent micturition, and cough;
* Know treatment to comorbid sleep disorders, such as sleep apnea or narcolepsy;
* Work on shift or on night shift;
* Concomitant pharmacological treatment or herbal medicines for insomnia within the past month;
* Known severe medical conditions, such as cardiovascular, liver, kidney or hematopoietic system disease, diabetes mellitus, cancers, cerebrovascular diseases;
* Impaired hematological profile and liver / renal function exceeds the upper limit of the reference value by 2 times;
* Known alcohol and / or drug abuse;
* Known allergic history to any Chinese herbal medicines;
* Diagnosed to be deficiency of spleen according to TCM theory;
* Any contraindications for taking Chinese medicines in the opinion of the investigators;
* Know pregnant or lactating; and
* Involved in other interventional clinical studies at the same time.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese University of Hong Kong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Lin Zhixiu
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhixiu Lin
Role: PRINCIPAL_INVESTIGATOR
Chinese University of Hong Kong
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Insomnia study
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.